Features
IL-6 Inhibition as a Treatment for Noninfectious Uveitis
Understanding interleukin-6 signaling sheds light on novel biologics that could benefit patients with refractory NIU.
By Naveen Karthik, MD, Dilraj S. Grewal, MD, FASRS
Expanding the Role of Suprachoroidal Injections
Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.
By Thomas A. Ciulla, MD, MBA
Incorporating AI Into Global ROP Care
Advances in imaging and machine learning offer new opportunities to standardize diagnosis and improve access worldwide.
By Amy Song, BA, Noelle Whitestone, MHA, Karyn E. Jonas, MSN, et al.
Brachytherapy for Uveal Melanoma: Is the Dose Too High?
Lower radiation doses and personalized plaque design could balance tumor control with vision preservation.
By Jose J. Echegaray, MD, Soumaya Bouhout, MD, Arun D. Singh, MD
Web Exclusives
Diagnosis and Management of Retinal Vasoproliferative Tumors
Early recognition and timely intervention are critical for preventing vision loss from VPTs.
By Arun D. Singh, MD, Soumaya Bouhout, MD
Departments
Reflections from ASRS
Upfront: This issue features articles on ocular oncology, pediatric retina, and emerging treatments for uveitis.
By Diana V. Do, MD
The Port Delivery System in the Paradigm
Controversies in Care: Experts assess the current role and future potential of Genentech’s Susvimo in patient care.
By Michael Colucciello, MD, Dante J. Pieramici, MD, FASRS, Carl C. Awh, MD
Uveitis Coding Considerations
Coding: Accurate documentation and coding are necessary to reflect the variable presentation of uveitis and its systemic associations.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update September 2025
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Supported Content
Two Specialties, One System
How UNITY VCS Is Transforming Ophthalmic Surgery at Duke Eye Center
By Dr. Kourtney Houser, Dr. Lejla Vajzovic